Clinical Trials · NCT07782359
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
- Phase
- Phase 1
- Recruitment status
- Not Yet Recruiting
- Sponsor
- University of Chicago
- Enrollment
- 30
- Start date
- Oct 2026
- Locations
- 1 site, United States
- Primary endpoint
- Body weight changes